Clinical trials have reported promising efficacy by combining HMAs with the CD70-specific monoclonal antibody Cusatuzumab, resulting in the elimination of LSCs and the induction of hematological responses in patients with AML, with 8 out of 12 patients achieving complete remission24. Here, CD70 is linked to acute myeloid leukemia.